Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRxâ"¢ into pharmacy client point-of-sales systems has commenced EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026 Manufacturer supplier relationship expansion effort focused on d ...

Core Insights - Wellgistics Health, Inc. has launched the diabetes prescription drug Brenzavvy® targeting 33 million Americans diagnosed with type II diabetes, primarily through its network of 6,500 independent pharmacies [1][4] - The SGLT-2 inhibitor market, which includes drugs like Jardiance®, reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the U.S. accounting for 40.8% of this market [2][4] - The proprietary EinsteinRx™ artificial intelligence platform will assist pharmacists in optimizing therapy selection and educating providers about Brenzavvy's benefits compared to other SGLT-2 inhibitors [2][3] Company Overview - Wellgistics Health integrates its EinsteinRx™ AI platform with a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the prescription drug dispensing process [4][5] - The company aims to improve patient access to medications while providing revenue opportunities for pharmacists through patient education on Brenzavvy [3][4] - The launch of Brenzavvy establishes a new model for next-generation drugs that offer specific advantages over established market leaders [4] Market Context - A significant gap exists in the prescription of SGLT-2 inhibitors, with only 11.9% of eligible diabetic patients receiving guideline-recommended prescriptions, indicating a need for improved care [2] - The launch of Brenzavvy is positioned to address the high out-of-pocket costs faced by many patients, particularly those who are uninsured or underinsured [4]

TAMPA, FLORIDA / ACCESS Newswire / December 4, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRxâ"¢ artificial intelligence prescription drug routing into blockchain-enabled smart contracts platform PharmacyChainâ"¢ to optimize the prescription medicines reimbursement and dispensing journey, today announced that it set a record date of December 19, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin. ...

Group 1 - The company plans to distribute Dream Bowl 2026 Meme Coin to shareholders with a record date and distribution date expected in December 2025 [1] - Distribution of the Meme Coin is anticipated to occur in January 2026 [1] - Wellgistics Health, Inc. is involved in the DataVault AI Shareholder Distribution Plan and is sponsoring Dream Bowl 2026 [1] Group 2 - Wellgistics is a leader in health information technology, utilizing EinsteinRx™ artificial intelligence for prescription routing [1] - The company employs PharmacyChain™ blockchain-enabled smart contracts to enhance the tracking and dispensing of prescription drugs [1] - The technology aims to optimize insurance coverage from manufacturers to patients [1]

Core Insights - Wellgistics is positioned to lead in the Web 3.0 Health Information Data Transfer within the $634 billion prescription drug industry through an exclusive licensing agreement with Datavault AI [1][2][6] - The implementation of Wellgistics' EinsteinRx AI hub is expected to optimize automated prescription fulfillment for various stakeholders including manufacturers, pharmacies, and patients [1][4][6] - Datavault's intellectual property enables smart contracts that create a barrier to entry in the $4.9 trillion US healthcare market [1][2] Company Overview - Wellgistics Health, based in Tampa, Florida, specializes in optimizing medication delivery from manufacturers to patients, connecting over 6,500 pharmacies and 200 manufacturers [3][9] - The PharmacyChain initiative aims to digitize the tracking of prescription drugs, ensuring accurate delivery and recommendations for safe use [3][5] Technology and Innovation - The completion of the EinsteinRx AI hub integrates Wellgistics' IT and physical infrastructure, enhancing the efficiency of prescription fulfillment and reducing costs associated with pharmacy benefits managers (PBMs) [4][5][6] - Wellgistics aims to minimize or eliminate PBM rebates, thereby reducing administrative burdens for payers and improving the overall pharmaceutical distribution process [6][7] Market Potential - PwC estimates a $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized system [2] - The integration of smart contracts into Wellgistics' operations is expected to significantly improve cost efficiency in the prescription filling process, benefiting various stakeholders in the healthcare ecosystem [6][7]